To hear about similar clinical trials, please enter your email below
Trial Title:
New Antigens Against Glioblastoma
NCT ID:
NCT05917821
Condition:
Glioblastoma Multiforme
Conditions: Official terms:
Glioblastoma
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
In this study the investigators will select and develop potential therapeutic monoclonal
antibodies (mAbs) for glioblastoma (GB). Activities include tissue microarray (TMA) to
test monoclonal antibodies specificity and target distribution, selection of glioblastoma
specific functional monoclonal antibodies, identification of candidate targets.
Criteria for eligibility:
Study pop:
National monocentric study, enrolling approximately 120 patients with glioblastoma, males
and females, no pedriatic age.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- age > 18 years;
- Written informed consent
Exclusion Criteria:
- Not-availability of informed consent
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Start date:
August 1, 2023
Completion date:
September 30, 2027
Lead sponsor:
Agency:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Agency class:
Other
Source:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05917821
